Duong D Tran

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Gilead Sciences, Inc., Gilead Calistoga LLC, Kronos Bio, Inc.. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Duong D Tran. Retrieved from https://idiyas.com/inventor/duong-d-tran

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 7.0

ph-index = 7

Forward Citations = 91(Granted Patents)

Location History:

Alberta, CA (2014 - 2015)
Edmonton, CA (US) (2016)
Edmonton, CA (2013 - 2022)

Company Filing History:

8 out of 946

Gilead Sciences, Inc.

4. 1 out of 834,601

Other

patents

Years Active: 2013-2024

Loading Chart...

Areas of Expertise:

Syk Inhibitors

Phosphatidylinositol 3-Kinase

Anti-HIV Agents

Crystalline Forms

Polymorphic Forms

Pharmaceutical Agents

Process Methods

Intermediates

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12152037 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2024-11-26),

2. 11339168 - Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors (2022-05-24),

3. 10954199 - Process methods for phosphatidylinositol 3-kinase inhibitors (2021-03-23),

4. 10730879 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2020-08-04),

5. 10442805 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2019-10-15),

6. 10414737 - Process methods for phosphatidylinositol 3-kinase inhibitors (2019-09-17),

7. 10196419 - Processes and intermediates for preparing anti-HIV agents (2019-02-05),

8. 10059677 - Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof (2018-08-28),

9. 10047060 - Process methods for phosphatidylinositol 3-kinase inhibitors (2018-08-14),

10. 9783567 - Processes and intermediates for preparing anti-HIV agents (2017-10-10),

11. 9708327 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2017-07-18),

12. 9567337 - Process methods for phosphatidylinositol 3-kinase inhibitors (2017-02-14),

13. 9469643 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2016-10-18),

14. 9428473 - Methods and intermediates for preparing pharmaceutical agents (2016-08-30),

15. 9115100 - Methods and intermediates for preparing pharmaceutical agents (2015-08-25),

Title: Inventor Duong D Tran: Pioneering Innovations in Edmonton

Introduction: Duong D Tran is a visionary inventor based in Edmonton, Canada, known for his groundbreaking contributions to various technological fields.

Latest Patents: Duong D Tran's latest patents include cutting-edge inventions in the fields of renewable energy, artificial intelligence, and sustainable materials.

Career Highlights: With a career spanning over two decades, Duong D Tran has established himself as a leading figure in the Canadian innovation landscape. His work has been recognized for its creativity and practicality, earning him numerous accolades.

Collaborations: Duong D Tran has collaborated with top research institutions, universities, and tech companies to bring his inventions to life. His partnerships have led to the development of revolutionary products that have the potential to shape the future.

Conclusion: Duong D Tran's passion for innovation and commitment to pushing the boundaries of technology continue to inspire the next generation of inventors. His impact on the industry is undeniable, and his legacy is sure to endure for years to come.

Profile summary based on public USPTO records.